Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats - PubMed (original) (raw)

Comparative Study

. 1998 Nov;43(11):2518-25.

doi: 10.1023/a:1026606904531.

Affiliations

• PMID: 9824145
• DOI: 10.1023/a:1026606904531

Comparative Study

Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats

M J Palmen et al. Dig Dis Sci. 1998 Nov.

Abstract

Glucocorticosteroids (GCS) are effective in treatment of inflammatory bowel disease (IBD), but also have unwanted systemic side effects. Here, we describe the effects of budesonide and dexamethasone on acute experimental colitis and on T cells in thymus and spleen, as well as the effect of budesonide treatment on relapsing colitis. Acute colitis was induced by intracolonic administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) in ethanol, and a relapse was induced by an intraperitoneal booster of TNBS. GCS were administered intrarectally on days 1, 4, and 6 after induction of acute colitis or a relapse. Inflammatory cells in the colon were studied on day 7, and in acute colitis also on days 13 and 16. Budesonide treatment in acute and relapsing colitis resulted in reduction of macroscopic damage and decreased the numbers of macrophages and neutrophils in the colon. Dexamethasone was less effective. Dexamethasone, but not budesonide, reduced the number of T cells in the thymus. It is concluded that local budesonide is more effective in treatment of acute experimental colitis than dexamethasone and, in contrast to dexamethasone, did not cause a general suppression of T cells. Although budesonide was very effective in the treatment of relapsing colitis, this effect was not accomplished by affecting the number of T cells in the colon.

PubMed Disclaimer

Similar articles

• The mechanism of altered neural function in a rat model of acute colitis.
  Jacobson K, McHugh K, Collins SM. Jacobson K, et al. Gastroenterology. 1997 Jan;112(1):156-62. doi: 10.1016/s0016-5085(97)70230-0. Gastroenterology. 1997. PMID: 8978354
• Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
  Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Daniel C, et al. J Pharmacol Exp Ther. 2008 Jan;324(1):23-33. doi: 10.1124/jpet.107.127209. Epub 2007 Oct 2. J Pharmacol Exp Ther. 2008. PMID: 17911375
• CD4+ T cells from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis rodents migrate to the recipient's colon upon transfer; down-regulation by CD8+ T cells.
  Palmen MJ, Wijburg OL, Kunst IH, Kroes H, van Rees EP. Palmen MJ, et al. Clin Exp Immunol. 1998 May;112(2):216-25. doi: 10.1046/j.1365-2249.1998.00564.x. Clin Exp Immunol. 1998. PMID: 9649183 Free PMC article.
• Budesonide modified-release capsules.
  Baker DE. Baker DE. Rev Gastroenterol Disord. 2001;1(3):147-55. Rev Gastroenterol Disord. 2001. PMID: 12120182 Review.
• The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
  Rutgeerts P. Rutgeerts P. Mediators Inflamm. 1998;7(3):137-40. doi: 10.1080/09629359891036. Mediators Inflamm. 1998. PMID: 9705597 Free PMC article. Review.

Cited by

• Damage to the enteric nervous system in experimental colitis.
  Sanovic S, Lamb DP, Blennerhassett MG. Sanovic S, et al. Am J Pathol. 1999 Oct;155(4):1051-7. doi: 10.1016/S0002-9440(10)65207-8. Am J Pathol. 1999. PMID: 10514387 Free PMC article.
• A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.
  Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, Suramanyam B, Guilford WJ, Parkinson JF. Fiorucci S, et al. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15736-41. doi: 10.1073/pnas.0404722101. Epub 2004 Oct 25. Proc Natl Acad Sci U S A. 2004. PMID: 15505205 Free PMC article.
• Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.
  Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR, Grimm MC. Newman R, et al. Clin Exp Immunol. 2005 Mar;139(3):411-20. doi: 10.1111/j.1365-2249.2005.02673.x. Clin Exp Immunol. 2005. PMID: 15730386 Free PMC article.
• Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.
  Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD. Banner KH, et al. Br J Pharmacol. 2004 Nov;143(5):590-8. doi: 10.1038/sj.bjp.0705982. Epub 2004 Oct 4. Br J Pharmacol. 2004. PMID: 15466445 Free PMC article.
• Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.
  Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J. Desreumaux P, et al. J Exp Med. 2001 Apr 2;193(7):827-38. doi: 10.1084/jem.193.7.827. J Exp Med. 2001. PMID: 11283155 Free PMC article.

References

1. 1. Clin Exp Immunol. 1995 Feb;99(2):226-32 - PubMed
2. 1. Am J Physiol. 1995 Jul;269(1 Pt 1):G119-25 - PubMed
3. 1. Eur J Immunol. 1982 Jun;12(6):511-8 - PubMed
4. 1. Aliment Pharmacol Ther. 1994 Aug;8(4):433-41 - PubMed
5. 1. J Immunol. 1989 May 15;142(10):3378-83 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.